Address: Frankfurter Str. 250
64293 Darmstadt ,Germany
Tel: +49 (0) 6151 72-0
Web: http://www.merck.de/de/index.html
Merck is a global pharmaceutical and chemical enterprise with around 33,000 employees in 60 countries and total revenues of € 7.6 billion (2008). The Pharmaceuticals business sector comprises innovative prescription drugs as well as over-the-counter products. The Chemicals business sector offers specialty products for the electronics, printing, coatings, cosmetics, pharmaceutical and biotech industries.The operational business is managed under the umbrella of Merck KGaA headquartered in Darmstadt (Germany). Around 30% of the company’s total capital is publicly traded, while the Merck family owns an interest of about 70% via the general partner E. Merck KG.Merck is the world’s oldest pharmaceutical and chemical company – its roots date back to 1668. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.
Anders Wesslau, the newly appointed general manager for Merck KGaA’s business units in Sweden, underlines how Merck’s healthcare business is a well-integrated player in the innovative Swedish life sciences ecosystem,…
Rogier Janssens, GM of the Biopharma business of Merck KGaA, Darmstadt, Germany in China, shares the highlights of his first 16 months at the affiliate; the impact of the regulatory…
Oskar Möbert, vice president of Veeva OpenData, discusses how standardizing customer reference data and systems organization-wide can help biopharmas scale globally and become more agile in their business. Data…
The biggest pharma industry and healthcare stories from Germany, including the country’s legalisation of cannabis; the MASH potential of Boehringer Ingelheim’s obesity candidate; Bayer’s further share price drop and expansion…
Pharma is rushing to adopt AI-driven tools in the hope of revolutionizing everything from drug discovery to clinical trials, regulatory submissions, and marketing efforts. While AI is the technology du…
Susanne Schaffert’s over 20-year stint at Novartis culminated with her presidency of the Swiss giant’s global oncology division, but when the company underwent a major restructure in 2022, she found…
As head of digital transformation at Bayer, Saskia Steinacker is well placed to unpack the hype around artificial intelligence in healthcare. In a wide-ranging interview, she explains how AI is…
Rainer Westermann of venture capitalist coalition Life Sciences Acceleration Alliance reviews the potential impact of the EU’s general pharmaceutical legislation on the investment climate for the EU life sciences sector.…
The latest pharma industry news from Germany, including Lilly’s new German plant; Bayer’s aborted anti-clotting drug trial and legal worries; Boehringer Ingelheim’s acquisition of Swiss biotech T3 Pharmaceuticals, and Hermes…
After positions at Novartis and Merck, Bettina Bauer, a trained scientist, joined Gilead in 2019 as VP and general manager of its German affiliate. Today, as the VP of the…
Merck’s Kaushal Kishore attempts to illustrate why pharma companies have struggled to crack what he calls “the Gross to Net (GtN) code.” He outlines the maturity journey for a pharma…
Patents can be an excellent way to demonstrate value, not only showing that a technology is protected but also how promising it can be when it eventually comes to market.…
The rise of niche therapies is shaping a more tailored engagement model, driven by data and AI, writes Florian Schnappauf, vice president of enterprise commercial strategy at Veeva Europe. …
Following the COVID-19 pandemic and the resulting supply chain disruptions, global drug pricing and access reforms have multiplied. The Inflation Reduction Act (IRA) has been introduced in the US while…
See our Cookie Privacy Policy Here
